Nanjing Ajinomoto Bio-Pharma Services and Amphastar Pharmaceuticals (NASDAQ: AMPH) announced on August 12, 2025, the signing of a licensing agreement covering three of Ajinomoto’s preclinical candidate compounds (PCCs). These compounds target oncology and wet age-related macular degeneration (wAMD). Amphastar will oversee development and commercialization in North America.
Agreement Details
Under the terms of the agreement, Amphastar will be responsible for the development and commercialization of the three products in North America. Ajinomoto will receive a total of $453 million, which includes an upfront payment, milestone payments, and sales royalties.
Product Highlights
The three products are based on Ajinomoto’s globally recognized innovative peptide research and development platform:
- Endogenous Micropeptide-Based Drug: This is the world’s first drug development based on an endogenous micropeptide. It has demonstrated significant efficacy against various tumors.
- Computer-Aided Formulation for wAMD: This new formulation molecule for wAMD treatment features a peptide structure designed with computer assistance, representing a breakthrough from traditional intravitreal injection administration.
- Peptide-Drug Conjugate (PDC): This is China’s first internationally licensed PDC molecule. It combines high selectivity, permeability, and safety, with improved physicochemical properties to achieve the regression of large-volume tumors.-Fineline Info & Tech
